Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?

Leukemia Research

Volumn 35, Issue 1, 2011, Pages

  Kimura, Shun ichi ^a   Kako, Shinichi ^a   Wada, Hidenori ^a   Sakamoto, Kana ^a   Ashizawa, Masahiro ^a   Sato, Miki ^a   Terasako, Kiriko ^a   Kikuchi, Misato ^a   Nakasone, Hideki ^a   Okuda, Shinya ^a   Yamazaki, Rie ^a   Oshima, Kumi ^a   Nishida, Junji ^a   Watanabe, Takuro ^b   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Saitama City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; BLOOD SAMPLING; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BEVERAGES; CITRUS; DRUG COSTS; FOOD-DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 78650173422     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.014     Document Type: Letter

References (5)

1. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
2. Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005, 44:879-894.
3. Guo L.Q., Fukuda K., Ohta T., Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000, 28:766-771.
4. Ducharme M.P., Warbasse L.H., Edwards D.J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995, 57:485-491.
5. Dutreix C., Peng B., Mehring G., Hayes M., Capdeville R., Pokorny R., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004, 54:290-294.